Portal hemodynamic effects of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma: a prospective cohort study

Portal hemodynamic effects of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma: a prospective cohort study - Portal hemodynamic effects ofatezolizumab and bevacizumab

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043366

Enrollment

Registered

2021-02-18

Start date

2021-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with advanced hepatocellular carcinoma

Interventions

1200 mg of atezolizumab plus 15 mg per kilogram of body weight of bevacizumab intravenously every 3 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Advanced-stage HCC is confirmed by clinical analysis. 2) BCLC stage B2 or B3

Exclusion criteria

Exclusion criteria: 1)Tumor invasion in intrahepatic large vessels (Vp4) 2)hepatic encephalopathy, refractory ascites 3)hypertension (160/100 or higher.) 4)Severe renal function(eGFR<50ml/min)

Design outcomes

Primary

Measure	Time frame
Changes in portal venous area	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University School of Medicine Department of Gastroenterology, Internal Medicine

kiruha@kitasato-u.ac.jp0427788111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026